Tag Archives: pan-genotypic

After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?

Posted on by — No Comments ↓

SVR rates in recent DAA combination trials are really impressive.  Hardly a month goes by without yet another trial showing excellent efficacy in populations so far considered ‘difficult to treat’, like cirrhotics or post-liver transplant patients on immunosuppressive therapies.  This begs the question: is there still room for improvement?  Why Continue reading After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?→

Snapshot: HCV Drugs in Development

Posted on by — No Comments ↓

It’s becoming a daunting task to follow the field given the rapid-fire release of study results and the many recent submissions of new direct-acting antiviral (DAA) drugs. All will be given as cocktails, with or without interferon or ribavirin, and for various durations depending on genotype (GT) and other factors.  How Continue reading Snapshot: HCV Drugs in Development→